Early insulin initiation in type 2 diabetes: efficacy, safety, and clinical implications: a systematic review with narrative synthesis
Abstract
Aims/background: Early insulin initiation in type 2 diabetes mellitus (T2DM) is proposed to improve glycemic control, preserve β-cell function, and potentially reduce long-term complications. Evidence suggests that starting insulin within five years of diagnosis may offer additional metabolic benefits, but its clinical impact remains uncertain. This systematic review aimed to evaluate the efficacy, safety, and challenges of early insulin use in T2DM.
Methods: We systematically searched PubMed, Cochrane Library, Scopus, and Controlled Trials Register for studies published from 2010 to 2024, including adults with T2DM who initiated insulin within five years of diagnosis. Sixteen studies met inclusion criteria (9 RCTs, 7 observational), totaling 44, 045 participants. Two reviewers independently extracted data on glycemic outcomes, adverse events, and long-term complications. Risk of bias was assessed using the Cochrane tool for RCTs and the JBI checklist for observational studies. Due to substantial clinical and methodological heterogeneity, a meta-analysis was not performed, and findings were synthesized narratively.
Results: Early insulin therapy significantly reduced HbA1c (by 0.8-2.3%, p<0.05) and fasting glucose (by 1.2-2.4 mmol/L). Hypoglycemia occurred in 8-15% of insulin users compared to 3-10% with oral agents; severe episodes were rare (<2%). Weight gain over 2 kg was reported in nearly half of the studies.
Conclusion: Early insulin initiation improves glycemic…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 44 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.